Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

J. Cortes et al.

Summary: The addition of pembrolizumab to chemotherapy significantly improves overall survival in patients with advanced triple-negative breast cancer whose tumors express PD-L1 with a CPS of 10 or more.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab

Kosuke Ueda et al.

Summary: This study found that peripheral absolute lymphocyte count can predict the efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma. Low absolute lymphocyte count before treatment was associated with shorter progression-free survival and overall survival, while an increase in absolute lymphocyte count one month after treatment was associated with better efficacy.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase

Qi Xiong et al.

Summary: In small cell lung cancer patients, NLR at 6 weeks after treatment initiation appears to be a biomarker of response to anti-PD-1/PD-L1 antibody treatment.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Leisha A. Emens et al.

Summary: Understanding the impact of tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors in metastatic triple-negative breast cancer may help optimize patient and treatment selection. The study found that PD-L1 expression and CD8-positive cells had an influence on the efficacy of immunotherapy.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Article Multidisciplinary Sciences

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Cristina Valero et al.

Summary: The study demonstrates the association of higher neutrophil-to-lymphocyte ratio (NLR) with poorer survival outcomes and lower rates of response across multiple cancer types treated with immune checkpoint inhibitors (ICI). Combining NLR with tumor mutational burden (TMB) significantly increases the probability of benefit from ICI, with the low NLR/high TMB group showing the highest likelihood of benefit. These findings highlight the potential of NLR as a cost-effective and widely accessible biomarker for predicting response to ICI therapy.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study

Shogo Nakamoto et al.

Summary: The study focused on the impact of post-progression survival on overall survival in HER2-negative advanced breast cancer patients, revealing that a longer time to treatment failure was associated with significantly longer overall survival. Patients in the shorter time to treatment failure group who received paclitaxel plus bevacizumab therapy had significantly inferior overall survival, but subsequent eribulin therapy improved overall survival.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Multidisciplinary Sciences

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer

Shogo Nakamoto et al.

Summary: This study revealed that high ALC, low NLR, and high LMR are associated with longer TTF and OS in patients with HER2-negative ABC who underwent PB therapy. These systemic immunity markers may serve as predictive markers for the effectiveness of PB therapy in these patients.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

D. Miles et al.

Summary: Combining atezolizumab with paclitaxel did not improve PFS or OS in PD-L1-positive aTNBC patients, although it showed some advantage in unconfirmed best overall response rate and duration of response.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit

Shogo Nakamoto et al.

Summary: This study found that dynamic changes in absolute lymphocyte counts (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy can serve as predictive markers for survival benefit in advanced breast cancer patients.

ANTICANCER RESEARCH (2021)

Add to Collection

Article Oncology

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update

Beverly Moy et al.

Summary: This guideline provides recommendations on chemotherapy and targeted therapy for patients with HR-negative metastatic breast cancer, offering different treatment options based on patient's condition, such as combination chemotherapy, single-agent chemotherapy, or targeted therapy. Specific treatment options are also suggested for patients with different genetic mutations.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology